{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,24]],"date-time":"2026-03-24T07:31:12Z","timestamp":1774337472560,"version":"3.50.1"},"reference-count":38,"publisher":"Oxford University Press (OUP)","issue":"7","license":[{"start":{"date-parts":[[2025,11,12]],"date-time":"2025-11-12T00:00:00Z","timestamp":1762905600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,3,24]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>Omadacycline is a tetracycline antibiotic approved for the treatment of community-acquired bacterial pneumonia and possesses activity against pulmonary infections caused by Mycobacteroides abscessus (formerly Mycobacterium abscessus). Initial therapy for pulmonary M. abscessus disease often consists of a combination of intravenous agents, which may include intravenous omadacycline. The physical compatibility of omadacycline with other intravenous agents used in the treatment of pulmonary M. abscessus disease is unknown.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Physical compatibility of omadacycline 1\u2005mg\/mL was assessed via actual Y-site infusion with amikacin, azithromycin, cefoxitin, imipenem\/cilastatin, and linezolid. Assessments of the triple-agent combinations of omadacycline with linezolid plus amikacin and imipenem\/cilastatin plus amikacin were also performed. As needed, agents were reconstituted with sterile water for injection and diluted in 0.9% sodium chloride injection to typical clinical concentrations. Each combination was tested for compatibility using visual, laser light scattering, microscopy, pH, and turbidity assessments. Samples were taken from the start and end of a typical 30-minute omadacycline infusion and assessed immediately and again 2\u2005hours after mixing. All experiments were performed in triplicate.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>No physical incompatibility was demonstrated with any tested combination of agents with any method at any time point. Results were consistent across experiments.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>At clinical concentrations of agents used in the treatment of pulmonary M. abscessus disease, omadacycline appears to be physically compatible in dual-agent combinations in Y-site infusion with amikacin, azithromycin, cefoxitin, imipenem\/cilastatin, and linezolid, as well as in triple combinations of omadacycline plus imipenem\/cilastatin and amikacin and omadacycline plus linezolid and amikacin.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/ajhp\/zxaf299","type":"journal-article","created":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T12:59:41Z","timestamp":1762865981000},"page":"e269-e276","source":"Crossref","is-referenced-by-count":0,"title":["Physical compatibility of omadacycline with intravenous agents used in the treatment of\n                    <i>Mycobacteroides abscessus<\/i>\n                    pulmonary disease"],"prefix":"10.1093","volume":"83","author":[{"given":"David A","family":"Butler","sequence":"first","affiliation":[{"name":"Department of Clinical and Administrative Sciences, School of Pharmacy and Health Professions, Notre Dame of Maryland University , Baltimore, MD ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kelly","family":"Moolick","sequence":"additional","affiliation":[{"name":"Department of Pharmacy Practice, Albany College of Pharmacy and Health Sciences , Albany, NY ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2025,11,12]]},"reference":[{"key":"2026032401014168100_zxaf299-B1","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1513\/AnnalsATS.201804-236OC","article-title":"Incidence and prevalence of nontuberculous mycobacterial lung disease in a large U.S. managed care health plan, 2008-2015","volume":"17","author":"Winthrop","year":"2020","journal-title":"Ann Am Thorac Soc"},{"key":"2026032401014168100_zxaf299-B2","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1016\/j.ijid.2022.10.013","article-title":"Global trends of pulmonary infections with nontuberculous mycobacteria: a systematic review","volume":"125","author":"Dahl","year":"2022","journal-title":"Int J Infect Dis"},{"issue":"4","key":"2026032401014168100_zxaf299-B3","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1093\/cid\/ciad214","article-title":"Epidemiology of pulmonary and extrapulmonary nontuberculous mycobacteria infections at 4 US emerging infections program sites: a 6-month pilot","volume":"77","author":"Grigg","year":"2023","journal-title":"Clin Infect Dis"},{"key":"2026032401014168100_zxaf299-B4","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1093\/cid\/ciaa241","article-title":"Treatment of nontuberculous mycobacterial pulmonary disease: an official ATS\/ERS\/ESCMID\/IDSA clinical practice guideline","volume":"71","author":"Daley","year":"2020","journal-title":"Clin Infect Dis"},{"key":"2026032401014168100_zxaf299-B5","doi-asserted-by":"crossref","first-page":"e13588","DOI":"10.1111\/ctr.13588","article-title":"Management of infections due to nontuberculous mycobacteria in solid organ transplant recipients \u2014 guidelines from the American Society of Transplantation Infectious Diseases Community of Practice","volume":"33","author":"Longworth","year":"2019","journal-title":"Clinical Transplant"},{"issue":"suppl 1","key":"2026032401014168100_zxaf299-B6","doi-asserted-by":"crossref","first-page":"i1","DOI":"10.1136\/thoraxjnl-2015-207360","article-title":"US Cystic Fibrosis Foundation and European Cystic Fibrosis Society consensus recommendations for the management of non-tuberculous mycobacteria in individuals with cystic fibrosis","volume":"71","author":"Floto","year":"2016","journal-title":"Thorax"},{"key":"2026032401014168100_zxaf299-B7","doi-asserted-by":"crossref","first-page":"ii1","DOI":"10.1136\/thoraxjnl-2017-210927","article-title":"British Thoracic Society guidelines for the management of non-tuberculous mycobacterial pulmonary disease (NTM-PD)","volume":"72","author":"Haworth","year":"2017","journal-title":"Thorax"},{"issue":"7","key":"2026032401014168100_zxaf299-B8","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1038\/s41579-020-0331-1","article-title":"Non-tuberculous mycobacteria and the rise of Mycobacterium abscessus","volume":"18","author":"Johansen","year":"2020","journal-title":"Nat Rev Microbiol"},{"issue":"7","key":"2026032401014168100_zxaf299-B9","doi-asserted-by":"crossref","first-page":"1454","DOI":"10.3390\/microorganisms10071454","article-title":"Mycobacterium abscessus: it\u2019s complex","volume":"10","author":"Abdelaal","year":"2022","journal-title":"Microorganisms"},{"issue":"3","key":"2026032401014168100_zxaf299-B10","doi-asserted-by":"crossref","first-page":"115882","DOI":"10.1016\/j.diagmicrobio.2022.115882","article-title":"In vitro susceptibility patterns for rapidly growing nontuberculous mycobacteria in the United States","volume":"105","author":"Hunkins","year":"2023","journal-title":"Diagn Microbiol Infect Dis"},{"key":"2026032401014168100_zxaf299-B11","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.jgar.2024.04.004","article-title":"Clinical characteristics and antimicrobial susceptibility profiles of Mycobacterium abscessus and Mycobacterium massiliense pulmonary infection","volume":"38","author":"Guo","year":"2024","journal-title":"J Glob Antimicrob Resist"},{"issue":"3","key":"2026032401014168100_zxaf299-B12","doi-asserted-by":"crossref","first-page":"116663","DOI":"10.1016\/j.diagmicrobio.2024.116663","article-title":"In vitro activity of omadacycline against geographically diverse rapidly growing nontuberculous mycobacteria (NTM) clinical isolates","volume":"111","author":"Terschl\u00fcsen","year":"2025","journal-title":"Diagn Microbiol Infect Dis"},{"issue":"5","key":"2026032401014168100_zxaf299-B13","doi-asserted-by":"crossref","first-page":"e02522","DOI":"10.1128\/AAC.02522-18","article-title":"In vitro activities of omadacycline against rapidly growing mycobacteria","volume":"63","author":"Shoen","year":"2019","journal-title":"Antimicrob Agents Chemother"},{"key":"2026032401014168100_zxaf299-B14","author":"Nuzyra (omadacycline)"},{"key":"2026032401014168100_zxaf299-B15","doi-asserted-by":"crossref","first-page":"e0323822","DOI":"10.1128\/spectrum.03238-22","article-title":"In vitro antimicrobial activities of tigecycline, eravacycline, omadacycline, and sarecycline against rapidly growing mycobacteria","volume":"11","author":"Zhang","year":"2023","journal-title":"Microbiol Spectr"},{"issue":"9","key":"2026032401014168100_zxaf299-B16","doi-asserted-by":"crossref","first-page":"e01135","DOI":"10.1128\/AAC.01135-17","article-title":"Comparison of omadacycline and tigecycline pharmacokinetics in the plasma, epithelial lining fluid, and alveolar cells of healthy adult subjects","volume":"61","author":"Gotfried","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"2026032401014168100_zxaf299-B17","doi-asserted-by":"crossref","first-page":"102482","DOI":"10.1016\/j.tube.2024.102482","article-title":"Efficacies of three drug regimens containing omadacycline to treat Mycobacteroides abscessus disease","volume":"146","author":"Rimal","year":"2024","journal-title":"Tuberculosis (Edinb)"},{"key":"2026032401014168100_zxaf299-B18","doi-asserted-by":"crossref","first-page":"e0082423","DOI":"10.1128\/aac.00824-23","article-title":"Long-term evaluation of clinical success and safety of omadacycline in nontuberculous mycobacteria infections: a retrospective, multicenter cohort of real-world health outcomes","volume":"67","author":"El Ghali","year":"2023","journal-title":"Antimicrob Agents Chemother"},{"key":"2026032401014168100_zxaf299-B19","doi-asserted-by":"crossref","first-page":"ofad335","DOI":"10.1093\/ofid\/ofad335","article-title":"Long-term safety and tolerability of omadacycline for the treatment of Mycobacterium abscessus infections","volume":"10","author":"Mingora","year":"2023","journal-title":"Open Forum Infect Dis"},{"key":"2026032401014168100_zxaf299-B20","author":"Winthrop"},{"key":"2026032401014168100_zxaf299-B21"},{"key":"2026032401014168100_zxaf299-B22","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1093\/cid\/ciy745","article-title":"Infectious Diseases Society of America clinical practice guideline for the management of outpatient parenteral antimicrobial therapy","volume":"68","author":"Norris","year":"2018","journal-title":"Clin Infect Dis"},{"key":"2026032401014168100_zxaf299-B23","author":"Linezolid injection, solution"},{"key":"2026032401014168100_zxaf299-B24","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1016\/j.clinthera.2023.09.004","article-title":"Compatibility of omadacycline with select parenteral products in simulated Y-site administration","volume":"45","author":"Butler","year":"2023","journal-title":"Clin Ther"},{"key":"2026032401014168100_zxaf299-B25","doi-asserted-by":"crossref","first-page":"20503121221135570","DOI":"10.1177\/20503121221135568","article-title":"Prepared omadacycline for injection: nine-day stability and sterility in an elastomeric pump","volume":"10","author":"Bower","year":"2022","journal-title":"SAGE Open Med"},{"issue":"2","key":"2026032401014168100_zxaf299-B26","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1310\/hpj5202-132","article-title":"Y-site incompatibility between premix concentrations of vancomycin and piperacillin-tazobactam: do current compatibility testing methodologies tell the whole story?","volume":"52","author":"Kufel","year":"2017","journal-title":"Hosp Pharm"},{"key":"2026032401014168100_zxaf299-B27","unstructured":"Imipenem\/cilastatin sodium\/lactated Ringers injection [monograph] . In: Trissel\u2019s 2 Clinical Pharmaceutics Database [proprietary data]. Merative LP. Accessed March 10, 2025."},{"issue":"9","key":"2026032401014168100_zxaf299-B28","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1093\/ajhp\/59.9.853","article-title":"Visual compatibility of azithromycin with 24 commonly used drugs during simulated Y-site delivery","volume":"59","author":"Voytilla","year":"2002","journal-title":"Am J Health-Syst Pharm"},{"key":"2026032401014168100_zxaf299-B29","author":"Imipenem\/cilastatin sodium\/azithromycin cefoxitin sodium\/amikacin sulfate\/linezolid [monograph]"},{"issue":"3","key":"2026032401014168100_zxaf299-B30","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1093\/ajcp\/74.3.316","article-title":"In-vitro inactivation of aminoglycoside antibiotics by piperacillin and carbenicillin","volume":"74","author":"Hale","year":"1980","journal-title":"Am J Clin Pathol"},{"issue":"7","key":"2026032401014168100_zxaf299-B31","doi-asserted-by":"crossref","first-page":"850","DOI":"10.7164\/antibiotics.35.850","article-title":"Comparative aminoglycoside inactivation by beta-lactam antibiotics. Effects of a cephalosporin and six penicillins on five aminoglycosides","volume":"35","author":"Riff","year":"1982","journal-title":"J Antibiot (Tokyo)"},{"issue":"4","key":"2026032401014168100_zxaf299-B32","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1128\/AAC.24.4.474","article-title":"Stability of gentamicin, tobramycin, and amikacin in combination with four beta-lactam antibiotics","volume":"24","author":"Glew","year":"1983","journal-title":"Antimicrob Agents Chemother"},{"key":"2026032401014168100_zxaf299-B33","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1016\/j.scitotenv.2013.06.027","article-title":"pH and temperature effects on the hydrolysis of three \u03b2-lactam antibiotics: ampicillin, cefalotin and cefoxitin","volume":"466-467","author":"Mitchell","year":"2014","journal-title":"Sci Total Environ"},{"key":"2026032401014168100_zxaf299-B34","author":"Thermo Scientific"},{"issue":"14","key":"2026032401014168100_zxaf299-B35","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.2146\/ajhp170839","article-title":"Physical compatibility of plazomicin with select I.V. drugs during simulated Y-site administration","volume":"75","author":"Asempa","year":"2018","journal-title":"Am J Health-Syst Pharm"},{"issue":"10","key":"2026032401014168100_zxaf299-B36","doi-asserted-by":"crossref","first-page":"2162","DOI":"10.1016\/j.clinthera.2019.08.005","article-title":"Assessment of the physical compatibility of eravacycline and common parenteral drugs during simulated Y-site administration","volume":"41","author":"Avery","year":"2019","journal-title":"Clin Ther"},{"issue":"3","key":"2026032401014168100_zxaf299-B37","first-page":"e36007","article-title":"The impact of smart pump technology in the healthcare system: a scope review","volume":"15","author":"Alamer","year":"2023","journal-title":"Cureus"},{"issue":"11","key":"2026032401014168100_zxaf299-B38","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1007\/s40264-020-00986-5","article-title":"Human-based errors involving smart infusion pumps: a catalog of error types and prevention strategies","volume":"43","author":"Kirkendall","year":"2020","journal-title":"Drug Saf"}],"container-title":["American Journal of Health-System Pharmacy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ajhp\/advance-article-pdf\/doi\/10.1093\/ajhp\/zxaf299\/65277430\/zxaf299.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ajhp\/article-pdf\/83\/7\/e269\/65277430\/zxaf299.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ajhp\/article-pdf\/83\/7\/e269\/65277430\/zxaf299.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,24]],"date-time":"2026-03-24T05:02:34Z","timestamp":1774328554000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ajhp\/article\/83\/7\/e269\/8321919"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,12]]},"references-count":38,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2025,11,12]]},"published-print":{"date-parts":[[2026,3,24]]}},"URL":"https:\/\/doi.org\/10.1093\/ajhp\/zxaf299","relation":{},"ISSN":["1079-2082","1535-2900"],"issn-type":[{"value":"1079-2082","type":"print"},{"value":"1535-2900","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,4,1]]},"published":{"date-parts":[[2025,11,12]]}}}